Anti-C5a receptor antibodies
US10323097B2 · kind B2 · utility
7Cited by
24References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 2, 2016 |
| Grant date | Jun 18, 2019 |
| Priority date | — |
| Expiry date | Aug 20, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns human antibodies recognizing the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.